Segments (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended										12 Months Ended
	Dec. 31, 2014		Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013		Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Segment Reporting Information [Line Items]
Product revenues											$ 76,983		$ 68,161		$ 45,295
Revenue from services											8,666		11,658		1,749
Revenue from transfer of intellectual property											5,476		16,711		0
Operating (loss) income											(145,815)		(79,632)		(37,269)
Depreciation and amortization											14,927		15,216		10,160
Net loss from investment in investees											(3,587)		(11,456)		(2,062)
Total revenues	25,533		19,773	23,545	22,274	20,692		20,641	23,821	31,376	91,125		96,530		47,044
Assets	1,267,664	[1]				1,391,516	[1]				1,267,664	[1]	1,391,516	[1]
Goodwill	224,292	[1]				226,373	[1]				224,292	[1]	226,373	[1]	80,450
United States
Segment Reporting Information [Line Items]
Total revenues											14,142		28,369		1,749
Chile
Segment Reporting Information [Line Items]
Total revenues											29,154		31,650		26,514
Spain
Segment Reporting Information [Line Items]
Total revenues											21,323		18,800		6,124
Israel
Segment Reporting Information [Line Items]
Total revenues											20,638		13,252		7,655
Mexico
Segment Reporting Information [Line Items]
Total revenues											5,807		4,459		5,002
Uruguay
Segment Reporting Information [Line Items]
Total revenues											61		0		0
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Revenue from services											240		825		1,354
Revenue from transfer of intellectual property											0		0		0
Operating (loss) income											(27,725)		(24,473)		(15,628)
Depreciation and amortization											97		149		179
Net loss from investment in investees											0		0		0
Assets	95,094					209,539					95,094		209,539
Goodwill	0					0					0		0
Segment Reconciling Items
Segment Reporting Information [Line Items]
Operating (loss) income											(2,042)		(3,151)		(585)
Pharmaceutical | Operating Segments
Segment Reporting Information [Line Items]
Product revenues											76,983		68,161		45,295
Revenue from services											0		0		0
Revenue from transfer of intellectual property											5,285		15,160		0
Operating (loss) income											(94,401)		(29,809)		(6,797)
Depreciation and amortization											7,936		8,234		6,367
Net loss from investment in investees											(3,587)		(11,456)		(2,062)
Assets	1,064,498					1,065,033					1,064,498		1,065,033
Goodwill	173,327					175,408					173,327		175,408
Diagnostics | Operating Segments
Segment Reporting Information [Line Items]
Revenue from services											8,426		10,833		395
Revenue from transfer of intellectual property											191		1,551		0
Operating (loss) income											(21,647)		(22,199)		(14,259)
Depreciation and amortization											6,894		6,833		3,614
Net loss from investment in investees											0		0		0
Assets	108,072					116,944					108,072		116,944
Goodwill	$ 50,965					$ 50,965					$ 50,965		$ 50,965

[1] As of December 31, 2014 and December 31, 2013, total assets include $7.6 million and $6.7 million, respectively, and total liabilities include $12.1 million and $10.4 million, respectively, related to SciVac, previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 4.